Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy

References

• Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–2848.
   PubMed Web of Science ®Google Scholar
• Simons JM, Jacobs JG, Roijers JP, et al. Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study. Breast Cancer Res Treat. 2021;185(2):441–451.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. JCO. 2012;30(15):1796–1804.
   PubMedGoogle Scholar
• Zhao Y, Dong X, Li R, et al. Evaluation of the pathological response and prognosis following neoadjuvant chemotherapy in molecular subtypes of breast cancer. Onco Targets Ther. 2015;8:1511–1521.
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–2334.
   PubMed Web of Science ®Google Scholar
• Blanco Sánchez A, Yébenes L, Berjón A, et al. Evaluación de la respuesta patológica a quimioterapia neoadyuvante en cáncer de mama: correlación con el fenotipo molecular [evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: correlation with molecular phenotype]. Rev Esp Patol. 2021;54(1):8–16.
   PubMedGoogle Scholar
• Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–327.
   PubMed Web of Science ®Google Scholar
• WHO. Rolling updates for breast cancer. [cite 2021 May 30]. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
   Google Scholar
• Pathak M, Dwivedi SN, Deo SVS, et al. Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Syst Rev. 2018; 7(1):89.
   PubMedGoogle Scholar
• Weiss A, Bashour SI, Hess K, et al. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Res. 2018;20(1):27.
   PubMedGoogle Scholar
• Penault-Llorca F, Abrial C, Raoelfils I, et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008; 39(8):1221–1228.
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Litière S, Piccart M, et al. EORTC 10994/BIG 1-00 study investigators. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Ann Oncol. 2014;25(6):1128–1136.
   PubMed Web of Science ®Google Scholar
• Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and Local-Regional control of breast cancer. Surg Oncol Clin N Am. 2018;27(1):95–120.
   PubMed Web of Science ®Google Scholar
• Shintia C, Endang H, Diani K. Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL. Malays J Pathol. 2016;38(1):25–32.
   PubMed Web of Science ®Google Scholar
• Untch M, Konecny GE, Paepke S, et al. Current and future role of neoadjuvant therapy for breast cancer. Breast. 2014;23(5):526–537.
   PubMed Web of Science ®Google Scholar
• Omranipour R, Jalili R, Yazdankhahkenary A, et al. Evaluation of pathologic complete response (pCR) to neoadjuvant chemotherapy in Iranian breast cancer patients with estrogen receptor positive and HER2 negative and impact of predicting variables on pCR. Eur J Breast Health. 2020;16(3):213–218.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. 2010;116(6):1431–1439.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23(16):3676–3685.
   PubMed Web of Science ®Google Scholar
• Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and Meta-analysis. Breast. 2011;20(6):485–490.
   PubMed Web of Science ®Google Scholar
• Wang C, Chen J, Xu X, et al. Dual HER2 blockade in neoadjuvant treatment of HER2+ breast cancer: a meta-analysis and review. Technol Cancer Res Treat. 2020;19:153303382096072.
   Web of Science ®Google Scholar
• Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020;9(3):32.
   PubMed Web of Science ®Google Scholar
• Sharma P, Connolly RM, Roussos Torres ET, et al. Best foot forward: Neoadjuvant systemic therapy as standard of care in triple-negative and HER2-positive breast Cancer. Am Soc Clin Oncol Educ Book. 2020;40:1–16.
   Google Scholar
• Sharma P, López-Tarruella S, García-Saenz JA, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24(23):5820–5829.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–756.
   PubMed Web of Science ®Google Scholar
• Collins PM, Brennan MJ, Elliott JA, et al. Neoadjuvant chemotherapy for luminal a breast cancer: factors predictive of histopathologic response and oncologic outcome. Am J Surg. 2021;222(2):368–376.
   PubMed Web of Science ®Google Scholar
• Haque W, Verma V, Hatch S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170(3):559–567.
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 2013;10(9):494–506.
   PubMed Web of Science ®Google Scholar
• Wang J, Sang D, Xu B, et al. Value of breast cancer molecular subtypes and Ki67 expression for the prediction of efficacy and prognosis of neoadjuvant chemotherapy in a Chinese population. Medicine (Baltimore). 2016;95(18):e3518.
   PubMed Web of Science ®Google Scholar
• Tao M, Chen S, Zhang X, et al. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Medicine (Baltimore). 2017;96(51):e9384.
   PubMed Web of Science ®Google Scholar
• Evcimik T, Degerli MS, Bilgic T. The effect of prognostic factors on long-term protection in breast cancer. Cureus. 2020;12(6):e8878.
   PubMed Web of Science ®Google Scholar
• Samiei S, van Nijnatten TJA, de Munck L, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg. 2020;271(3):574–580.
   PubMed Web of Science ®Google Scholar
• Díaz-Casas SE, Castilla-Tarra JA, Pena-Torres E, et al. Pathological response to neoadjuvant chemotherapy and the molecular classification of locally advanced breast cancer in a Latin American cohort. Oncologist. 2019;24(12):e1360–e1370.
   PubMed Web of Science ®Google Scholar
• Jarząb M, Stobiecka E, Badora-Rybicka A, et al. Association of breast cancer grade with response to neoadjuvant chemotherapy assessed postoperatively. pjp. 2019;70(2):91–99.
   Google Scholar